Evidence map›Paper›PMID 37045546›Full record

ArticleInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2023

TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.

Miranda P Steenbeek, Majke H D van Bommel, Joanna intHout, Christine B Peterson, Michiel Simons, Kit C B Roes, Marleen Kets, Barbara M Norquist, Elizabeth M Swisher, Rosella P M G Hermens and 3 more

2 registry-linked trialsOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04294927 narecruitingnot on this map

TUBectomy With Delayed Oophorectomy as Alternative for Risk-reducing Salpingo-oophorectomy in High Risk Women to Assess the Safety of Prevention: TUBA-WISP II Study.

TypeinterventionalSponsorUniversity Medical Center NijmegenRan2020 to 2040Enrolled3,000ConditionsBRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene MutationArmsRisk-reducing salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy
NCT07532434 recruitingnot on this mapstarted 2025, after this paper: background citation

A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer

Typeobservational_patient_registrySponsorPeking University Third HospitalRan2025 to 2035Enrolled480ConditionsOvarian Cancer, Breast Cancer
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Article
  5. Complications Following Bilateral Salpingectomy by Indication: Population-Based Cohort Study.BJOG : an international journal of obstetrics and gynaecology · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Observational
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Miranda P SteenbeekObstetrics & Gynaecology, Radboudumc, Nijmegen, The Netherlands.ORCID 0000-0001-6097-1579
Majke H D van BommelObstetrics & Gynaecology, Radboudumc, Nijmegen, The Netherlands.ORCID 0000-0002-7562-9861
Joanna intHoutDepartment for Health Evidence, Radboudumc, Nijmegen, The Netherlands.
Christine B PetersonDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Michiel SimonsPatholoy, Radboudumc, Nijmegen, The Netherlands.
Kit C B RoesDepartment for Health Evidence, Radboudumc, Nijmegen, The Netherlands.
Marleen KetsHuman Genetics, Radboudumc, Nijmegen, The Netherlands.
Barbara M NorquistObstetrics & Gynecology, University of Washington, Seattle, Washington, USA.
Elizabeth M SwisherObstetrics & Gynecology, University of Washington, Seattle, Washington, USA.
Rosella P M G HermensScientific Institute for Quality of Healthcare, Radboudumc, Nijmegen, The Netherlands.
TUBA-WISP II consortium
Karen H LuGynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Joanne A de HulluObstetrics & Gynaecology, Radboudumc, Nijmegen, The Netherlands Joanne.deHullu@radboudumc.nl.
Radboud University Nijmegen · NLThe University of Texas MD Anderson Cancer Center · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRisk-reducing salpingectomy with delayed oophorectomy has gained interest for individuals at high risk for tubo-ovarian cancer as there is compelling evidence that especially high-grade serous carcinoma originates in the fallopian tubes. Two studies have demonstrated a positive effect of salpingectomy on menopause-related quality of life and sexual health compared with standard risk-reducing salpingo-oophorectomy. PRIMARY

objectiveTo investigate whether salpingectomy with delayed oophorectomy is non-inferior to the current standard salpingo-oophorectomy for the prevention of tubo-ovarian cancer among individuals at high inherited risk. STUDY HYPOTHESIS: We hypothesize that postponement of oophorectomy after salpingectomy, to the age of 40-45 ( TRIAL

designIn this international prospective preference trial, participants will choose between the novel salpingectomy with delayed oophorectomy and the current standard salpingo-oophorectomy. Salpingectomy can be performed after the completion of childbearing and between the age of 25 and 40 ( MAJOR INCLUSION/EXCLUSION CRITERIA: Premenopausal individuals with a documented class IV or V germline pathogenic variant in the PRIMARY ENDPOINT: The primary outcome is the cumulative tubo-ovarian cancer incidence at the target age: 46 years for SAMPLE SIZE: The sample size to ensure sufficient power to test non-inferiority of salpingectomy with delayed oophorectomy compared with salpingo-oophorectomy requires 1500 ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING

resultsParticipant recruitment is expected to be completed at the end of 2026 (total recruitment period of 5 years). The primary outcome is expected to be available in 2036 (minimal follow-up period of 10 years). TRIAL REGISTRATION NUMBER: NCT04294927.

Indexed as

Ovarian NeoplasmsSalpingo-oophorectomyAdultBRCA1 ProteinChild, PreschoolFemaleGenes, BRCA1Genetic Predisposition to DiseaseHumansMiddle AgedMutationOvariectomyProspective StudiesQuality of LifeSalpingectomyBRCA1 ProteinBRCA1 ProteinBRCA2 ProteinCarcinomaGynecologic Surgical ProceduresOvarian Cancer

Identifiers

PMID37045546
PMCPMC10314019
OpenAlexW4365141280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.